Table 3

Multivariate analysis of prognostic markers for PFS and OS (Cox proportional hazards regression)

The data set includes 69 PTs with relapsed MM who were treated with Thal for at least 3 months.

Interval analyzedaEstimated hazard ratio95% Confidence intervalP
PFS
 β2-Microglobulin (mg/liter)2.5–5.01.400.96–2.040.08
 Albumin (g/liter)35–450.820.33–1.990.66
 Hemoglobin (g/dl)9–120.890.40–1.990.78
 C-reactive protein (mg/liter)2–50.780.37–1.670.53
 Age (yrs)50–650.520.25–1.080.08
 Thal19.8–31.80.620.25–1.530.30
OS
 β2-Microglobulin (mg/liter)2.5–5.01.410.73–2.720.30
 Albumin (g/liter)35–450.670.13–3.430.63
 Hemoglobin (g/dl)9–120.200.06–0.700.01
 C-reactive protein (mg/liter)2–50.370.09–1.600.19
 Age (yrs)50–650.870.26–2.970.83
 Thal19.8–31.80.070.01–0.370.001
  • a In this statistical model, the effect on PFS and OS was analyzed for the indicated intervals of β2-microglobulin, albumin, hemoglobin, C-reactive protein, age, and the cumulative 3-month Thal dosage. These intervals are defined by the borderlines to the upper and lower quartiles. Additional parameters such as myeloma stage or type did not show a relevant effect in this statistical model.